108 related articles for article (PubMed ID: 15923160)
1. erb-b2 amplification by fluorescence in situ hybridization in breast cancer specimens read as 2+ in immunohistochemical analysis.
Lan C; Liu JM; Liu TW; Hsu DH; Liang S; Chen JR; Peng JW
Am J Clin Pathol; 2005 Jul; 124(1):97-102. PubMed ID: 15923160
[TBL] [Abstract][Full Text] [Related]
2. Analysis of ERBB2 and TOP2A gene status using fluorescence in situ hybridization versus immunohistochemistry in localized breast cancer.
Bouchalová K; Trojanec R; Kolár Z; Cwiertka K; Cernáková I; Mihál V; Hajdúch M
Neoplasma; 2006; 53(5):393-401. PubMed ID: 17013533
[TBL] [Abstract][Full Text] [Related]
3. The incidence of topoisomerase II-alpha genomic alterations in adenocarcinoma of the breast and their relationship to human epidermal growth factor receptor-2 gene amplification: a fluorescence in situ hybridization study.
Hicks DG; Yoder BJ; Pettay J; Swain E; Tarr S; Hartke M; Skacel M; Crowe JP; Budd GT; Tubbs RR
Hum Pathol; 2005 Apr; 36(4):348-56. PubMed ID: 15891995
[TBL] [Abstract][Full Text] [Related]
4. Topoisomerase IIalpha gene amplification in gastric carcinomas: correlation with the HER2 gene. An immunohistochemical, immunoblotting, and multicolor fluorescence in situ hybridization study.
Kanta SY; Yamane T; Dobashi Y; Mitsui F; Kono K; Ooi A
Hum Pathol; 2006 Oct; 37(10):1333-43. PubMed ID: 16949920
[TBL] [Abstract][Full Text] [Related]
5. Detection of C-erb B2 gene amplification in bilharzial associated bladder cancer using fluorescence in situ hybridization.
Aly MS; Khaled HM
Urol Oncol; 2004; 22(6):448-52. PubMed ID: 15610859
[TBL] [Abstract][Full Text] [Related]
6. Copy number analysis of c-erb-B2 (HER-2/neu) and topoisomerase IIalpha genes in breast carcinoma by quantitative real-time polymerase chain reaction using hybridization probes and fluorescence in situ hybridization.
Murthy SK; Magliocco AM; Demetrick DJ
Arch Pathol Lab Med; 2005 Jan; 129(1):39-46. PubMed ID: 15628907
[TBL] [Abstract][Full Text] [Related]
7. HER-2/neu and topoisomerase IIa gene amplification and protein expression in invasive breast carcinomas: chromogenic in situ hybridization and immunohistochemical analyses.
Bhargava R; Lal P; Chen B
Am J Clin Pathol; 2005 Jun; 123(6):889-95. PubMed ID: 15899781
[TBL] [Abstract][Full Text] [Related]
8. Topoisomerase IIalpha gene status and prediction of pathological complete remission after anthracycline-based neoadjuvant chemotherapy in endocrine non-responsive Her2/neu-positive breast cancer.
Orlando L; Del Curto B; Gandini S; Ghisini R; Pietri E; Torrisi R; Balduzzi A; Cardillo A; Dellapasqua S; Veronesi P; Viale G; Goldhirsch A; Colleoni M
Breast; 2008 Oct; 17(5):506-11. PubMed ID: 18456496
[TBL] [Abstract][Full Text] [Related]
9. TOP2A and HER2 gene amplification as predictors of response to anthracycline treatment in breast cancer.
Villman K; Sjöström J; Heikkilä R; Hultborn R; Malmström P; Bengtsson NO; Söderberg M; Saksela E; Blomqvist C
Acta Oncol; 2006; 45(5):590-6. PubMed ID: 16864174
[TBL] [Abstract][Full Text] [Related]
10. Topoisomerase IIalpha gene amplification predicts favorable treatment response to tailored and dose-escalated anthracycline-based adjuvant chemotherapy in HER-2/neu-amplified breast cancer: Scandinavian Breast Group Trial 9401.
; Tanner M; Isola J; Wiklund T; Erikstein B; Kellokumpu-Lehtinen P; Malmström P; Wilking N; Nilsson J; Bergh J
J Clin Oncol; 2006 Jun; 24(16):2428-36. PubMed ID: 16682728
[TBL] [Abstract][Full Text] [Related]
11. retrospective analysis of topoisomerase IIa amplifications and deletions as predictive markers in primary breast cancer patients randomly assigned to cyclophosphamide, methotrexate, and fluorouracil or cyclophosphamide, epirubicin, and fluorouracil: Danish Breast Cancer Cooperative Group.
Knoop AS; Knudsen H; Balslev E; Rasmussen BB; Overgaard J; Nielsen KV; Schonau A; Gunnarsdóttir K; Olsen KE; Mouridsen H; Ejlertsen B;
J Clin Oncol; 2005 Oct; 23(30):7483-90. PubMed ID: 16234514
[TBL] [Abstract][Full Text] [Related]
12. Characterization of topoisomerase II alpha gene amplification and deletion in breast cancer.
Järvinen TA; Tanner M; Bärlund M; Borg A; Isola J
Genes Chromosomes Cancer; 1999 Oct; 26(2):142-50. PubMed ID: 10469452
[TBL] [Abstract][Full Text] [Related]
13. Amplification of TOP2A and HER-2 genes in breast cancers occurring in patients harbouring BRCA1 germline mutations.
Hagen AI; Bofin AM; Ytterhus B; Maehle LO; Kjellevold KH; Myhre HO; Møller P; Lønning PE
Acta Oncol; 2007; 46(2):199-203. PubMed ID: 17453369
[TBL] [Abstract][Full Text] [Related]
14. Low-level TOP2A amplification in prostate cancer is associated with HER2 duplication, androgen resistance, and decreased survival.
Murphy AJ; Hughes CA; Barrett C; Magee H; Loftus B; O'Leary JJ; Sheils O
Cancer Res; 2007 Mar; 67(6):2893-8. PubMed ID: 17363613
[TBL] [Abstract][Full Text] [Related]
15. Gene copy mapping of the ERBB2/TOP2A region in breast cancer.
Jacobson KK; Morrison LE; Henderson BT; Blondin BA; Wilber KA; Legator MS; O'Hare A; Van Stedum SC; Proffitt JH; Seelig SA; Coon JS
Genes Chromosomes Cancer; 2004 May; 40(1):19-31. PubMed ID: 15034864
[TBL] [Abstract][Full Text] [Related]
16. Rates of topoisomerase II-alpha and HER-2 gene amplification and expression in epithelial ovarian carcinoma.
Mano MS; Awada A; Di Leo A; Durbecq V; Paesmans M; Cardoso F; Larsimont D; Piccart M
Gynecol Oncol; 2004 Mar; 92(3):887-95. PubMed ID: 14984957
[TBL] [Abstract][Full Text] [Related]
17. The topoisomerase II alpha gene status in primary breast cancer is a predictive marker of the response to anthracycline-based neoadjuvant chemotherapy.
Kawachi K; Sasaki T; Murakami A; Ishikawa T; Kito A; Ota I; Shimizu D; Nozawa A; Nagashima Y; Machinami R; Aoki I
Pathol Res Pract; 2010 Mar; 206(3):156-62. PubMed ID: 20089371
[TBL] [Abstract][Full Text] [Related]
18. C-erb-B2 gene amplification and serum level of c-erb-B2 oncoprotein at primary breast cancer diagnosis.
Fontana X; Ferrari P; Namer M; Peysson R; Salanon C; Bussiere F
Anticancer Res; 1994; 14(5B):2099-104. PubMed ID: 7840506
[TBL] [Abstract][Full Text] [Related]
19. HER-2 testing in breast cancer using immunohistochemical analysis and fluorescence in situ hybridization: a single-institution experience of 2,279 cases and comparison of dual-color and single-color scoring.
Lal P; Salazar PA; Hudis CA; Ladanyi M; Chen B
Am J Clin Pathol; 2004 May; 121(5):631-6. PubMed ID: 15151202
[TBL] [Abstract][Full Text] [Related]
20. Topoisomerase II-alpha gene deletion is not frequent as its amplification in breast cancer.
Park K; Han S; Gwak GH; Kim HJ; Kim J; Kim KM
Breast Cancer Res Treat; 2006 Aug; 98(3):337-42. PubMed ID: 16502015
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
